InMed Pharmaceuticals is the first company to advance cannabinol (CBN) into clinical trials for therapeutic development. It has begun a Phase 1 clinical trial in healthy volunteers for INM-755 CBN cream, its lead program in epidermolysis bullosa (EB). CBN is also the active pharmaceutical ingredient in InMed’s second program in glaucoma. In this video, InMed CEO Eric A. Adams talks about CBN’s distinct structural properties and its potential in treatments for skin and ocular diseases.
Fierce Biotech Article: Neuroinflammation a Key Underlying Factor in Alzheimer’s Disease Risk
Article featured in Fierce Biotech October 16, 2025 Excerpt: New findings discussed at the latest Alzheimer’s Association International Conference (AAIC) highlight the risk factors associated
October 27, 2025
